12967_2016_844_MOESM2_ESM.tif (877.67 kB)
MOESM2 of Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition
figure
posted on 2016-04-14, 05:00 authored by Jurjen Tel, Rutger Koornstra, Nienke Haas, Vincent Deutekom, Harm Westdorp, Steve Boudewijns, Nielka Erp, Stefania Blasio, Winald Gerritsen, Carl Figdor, I. Vries, Stanleyson HatoAdditional file 2: Fig S2. Indicated immune cell subsets were cultured in increasing concentrations of vemurafenib and cell viability was determined after 24Â h by FACS analysis. Shown is the mean (+SEM) of three independent experiments.